Levels of neurofilament light (NfL), a protein marker of neuronal damage, appear to capture some aspects of patient‐perceived physical and functional abilities with multiple sclerosis (MS), as well as their utilization of select healthcare services, a real-world study suggests. Its researchers, however, stress that more work is needed before NfL levels might be considered a relevant biomarker of a patient’s general quality of life. The study, “Serum neurofilament levels and patient‐reported outcomes in multiple sclerosis,” was published…

You must be logged in to read/download the full post.